<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940196</url>
  </required_header>
  <id_info>
    <org_study_id>EF-28</org_study_id>
    <nct_id>NCT03940196</nct_id>
  </id_info>
  <brief_title>Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)</brief_title>
  <official_title>ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovoCure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovoCure Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, randomized controlled phase III trial aimed to test the efficacy
      and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the
      treatment of recurrent ovarian cancer . The device is an experimental, portable, battery
      operated device for chronic administration of alternating electric fields (termed TTFields or
      TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAST PRE-CLINICAL AND CLINICAL EXPERIENCE:

      The effect of the electric fields (TTFields, TTF) has demonstrated significant activity in in
      vitro and in vivo ovarian carcinoma pre-clinical models both as a single modality treatment
      and in combination with chemotherapies. TTFields have been demonstrated to act
      synergistically with taxanes and have been shown to be additive when combined with other
      chemotherapies. In addition, TTFields have shown to inhibit metastatic spread of malignant
      melanoma in in vivo experiment.

      In a pilot study, 31 patients with recurrent platinum-resistant ovarian carcinoma received
      paclitaxel together with TTFields (200 kHz) applied to the abdomen/pelvis until disease
      progression. The combination was well tolerated and the only device-related adverse event was
      contact dermatitis.

      In addition, a phase III trial of Optune® (200 kHz) as monotherapy compared to active
      chemotherapy in recurrent glioblastoma patients showed TTFields to be equivalent to active
      chemotherapy in extending survival, associated with minimal toxicity, good quality of life,
      and activity within the brain (14% response rate). Finally, a phase III trial of Optune®
      combined with maintenance temozolomide compared to maintenance temozolomide alone has shown
      that combined therapy led to a significant improvement in both progression free survival and
      overall survival in patients with newly diagnosed glioblastoma without the addition of high
      grade toxicity and without decline in quality of life.

      DESCRIPTION OF THE TRIAL:

      All patients included in this trial are patients with platinum-resistant ovarian carcinoma.
      In addition, all patients must meet all eligibility criteria.

      Eligible patients will be randomly assigned to one of two groups:

        1. Patients receive TTFields at 200 kHz to the abdomen and pelvis using the NovoTTF-100L(O)
           System together with weekly paclitaxel.

        2. Patients receive weekly paclitaxel alone.

      Patients will be randomized at a 1:1 ratio. Baseline tests will be performed in patients
      enrolled in both arms. If assigned to the NovoTTF-100L(O) group, the patients will be treated
      continuously with the device until progression in the abdomen/pelvis. On both arms, patients
      who have progression outside the abdomen/pelvis will switch to a second line treatment
      according to local practice.

      SCIENTIFIC BACKGROUND:

      Electric fields exert forces on electric charges similar to the way a magnet exerts forces on
      metallic particles within a magnetic field. These forces cause movement and rotation of
      electrically charged biological building blocks, much like the alignment of metallic
      particles seen along the lines of force radiating outwards from a magnet.

      Electric fields can also cause muscles to twitch and if strong enough may heat tissues.
      TTFields are alternating electric fields of low intensity. This means that they change their
      direction repetitively many times a second. Since they change direction very rapidly (200
      thousand times a second), they do not cause muscles to twitch, nor do they have any effects
      on other electrically activated tissues in the body (brain, nerves and heart). Since the
      intensities of TTFields in the body are very low, they do not cause heating.

      The finding made by Novocure was that finely tuned alternating fields of very low intensity,
      now termed TTFields (Tumor Treating Fields), cause a significant slowing in the growth of
      cancer cells. Due to the unique geometric shape of cancer cells when they are multiplying,
      TTFields cause electrically-charged cellular components of these cells to change their
      location within the dividing cell, disrupting their normal function and ultimately leading to
      cell death. In addition, cancer cells also contain miniature building blocks which act as
      tiny motors in moving essential parts of the cells from place to place. TTFields interfere
      with the normal orientation of these tiny motors related to other cellular components since
      they are electrically-charged as well. As a result of these two effects, tumor cell division
      is slowed, results in cellular death or reverses after continuous exposure to TTFields.

      Other cells in the body (normal healthy tissues) are affected much less than cancer cells
      since they multiply at a much slower rate if at all. In addition TTFields can be directed to
      a certain part of the body, leaving sensitive areas out of their reach. Finally, the
      frequency of TTFields applied to each type of cancer is specific and may not damage normally
      dividing cells in healthy tissues.

      In conclusion, TTFields could potentially become treatment for ovarian cancer with very few
      side effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Next progression-free survival</measure>
    <time_frame>4 years</time_frame>
    <description>Measured from the time of randomization to tumor progression on next-line treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to undisputable deterioration in health-related quality of life (HRQoL)</measure>
    <time_frame>4 years</time_frame>
    <description>Measured as the time interval between randomization until the first decrease in HRQoL score ≥ 10-point with no further improvement in HRQoL score ≥ 10 points on any further HRQoL data, based on the EORTC QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first and second subsequent treatment</measure>
    <time_frame>4 years</time_frame>
    <description>Measured as the time from the date of randomization to the clinical decision made by the investigator to initiate a first and second subsequent lines of treatment, respectively, or death date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using the EORTC QLQ C30 questionnaire with the ovarian cancer symptom OV28 module.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity and frequency of adverse events</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>NovoTTF-100L(O)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive TTFields using the NovoTTF-100L(O) System together with weekly Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive best standard of care with weekly Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoTTF-100L(O)</intervention_name>
    <description>Patients receive continuous TTFields treatment using the NovoTTF-100L(O) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen/pelvis. The treatment enables the patient to maintain regular daily routine.</description>
    <arm_group_label>NovoTTF-100L(O)</arm_group_label>
    <other_name>TTFields</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 80 mg/m^2 intravenous infusion will be administered weekly for 8 weeks and then on Days 1, 8 and 15 of each subsequent 28-day cycle.</description>
    <arm_group_label>Best Standard of Care</arm_group_label>
    <arm_group_label>NovoTTF-100L(O)</arm_group_label>
    <other_name>Weekly Paclitaxel</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age and older

          2. Epithelial histology of ovarian/primary peritoneal or fallopian tube carcinoma at the
             time of diagnosis

          3. Life expectancy of ≥ 12 weeks

          4. Maximum two prior lines of systemic therapy following diagnosis of platinum-resistance

          5. Maximum total of 5 prior lines of systemic therapy

          6. Amenable to receive weekly paclitaxel and able to operate the NovoTTF-100L(O) System

          7. ECOG 0-1

          8. Evaluable (measurable or non-measurable) disease in the abdominal/pelvic region per
             RECIST V1.

          9. Signed informed consent form for the study protocol

        Exclusion Criteria:

          1. Primary platinum-refractory disease (progression per RECIST V1.1 during or within 1
             month after first line therapy), while secondary platinum-refractory disease is
             allowed

          2. Prior disease progression on a weekly paclitaxel for recurrent disease

          3. Brain metastasis or leptomeningeal spread of the tumor

          4. Albumin level &lt;25 gram/liter (subjects should not receive total parenteral nutrition
             or albumin within 2 weeks of the test)

          5. CTCAE V5.0 Grade 3 or higher peripheral neuropathy

          6. Implantable electrical medical devices

          7. Known allergies to medical adhesives or hydrogel

          8. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to paclitaxel or
             drugs similar or related to paclitaxel, except for cases that were able to undergo
             desensitization per investigator

          9. Prior malignancies treated primarily or for recurrence within 2 years prior to
             inclusion in this study, except for completely resected non-melanomatous skin
             carcinoma, or successfully treated in situ carcinoma of the skin, breast or cervix of
             the uterus

         10. Serious co-morbidities

         11. Concurrent anti-tumor therapy beyond weekly paclitaxel, excluding hormonal therapy for
             breast cancer

         12. Concurrent active treatment in another clinical trial. However prior participation in
             clinical trials is allowed as well as participation during survival follow-up

         13. Pregnancy or breast-feeding (female patients with reproductive potential and their
             partners must accept to use effective contraception throughout the entire study period
             and for 3 months after the end of treatment). All patients who are capable of becoming
             pregnant must take a pregnancy test which is negative within 72 hours before beginning
             treatment. The definition of effective contraception is left up to the decision of the
             investigator

         14. Admitted to an institution by administrative or court order
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignace Vergote, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven, Leuven Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonia Mahnig</last_name>
    <phone>+41414553632</phone>
    <email>Clinicaltrials@novocure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Kimbell</last_name>
      <phone>520-668-5678</phone>
      <email>Stacey.Kimbell@USONCOLOGY.COM</email>
    </contact>
    <investigator>
      <last_name>Joseph Buscema</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-336-3045</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>303-418-7600</phone>
    </contact_backup>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-336-3045</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>303-385-2000</phone>
    </contact_backup>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-336-3045</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>719-577-2555</phone>
    </contact_backup>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-336-3045</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>303-388-4876</phone>
    </contact_backup>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-336-3045</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>303-321-0302</phone>
    </contact_backup>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-336-3045</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>303-430-2700</phone>
    </contact_backup>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120-4413</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-336-3045</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>303-730-4700</phone>
    </contact_backup>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-336-3045</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>303-925-0700</phone>
    </contact_backup>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-336-3045</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>303-684-1900</phone>
    </contact_backup>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-336-3045</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>303-805-7744</phone>
    </contact_backup>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-336-3045</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>719-296-6000</phone>
    </contact_backup>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-336-3045</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>303-386-7622</phone>
    </contact_backup>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trena Davis</last_name>
      <phone>770-219-8822</phone>
      <email>trena.davis@nghs.com</email>
    </contact>
    <contact_backup>
      <phone>770-219-9000</phone>
    </contact_backup>
    <investigator>
      <last_name>Andrew Green</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Des Moines Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Peterson</last_name>
      <phone>515-241-3305</phone>
      <email>epeterson@iora.org</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Zarling</last_name>
      <phone>515.556.3260</phone>
      <email>aczarling@iora.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Behrens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-2025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesie Martinez</last_name>
      <phone>502-629-3696</phone>
      <email>Jesie.Martinez@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Mary Gordinier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>301-933-3216</phone>
    </contact>
    <investigator>
      <last_name>Cheryl Aylesworth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital &amp; Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Roache</last_name>
      <phone>781-744-5100</phone>
      <email>julia.roache@lahey.org</email>
    </contact>
    <investigator>
      <last_name>Corrine Zarwan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Heezen</last_name>
      <phone>612-884-6321</phone>
    </contact>
    <investigator>
      <last_name>Jessica Thomes-Pepin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynne Lippmann</last_name>
      <phone>314-362-1760</phone>
      <email>lippmannl@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kacie Gebhardt</last_name>
      <phone>314 362-2288</phone>
      <email>kgebhardt@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Premal Thaker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Estabrook Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114-4108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>402-354-7939</phone>
    </contact>
    <investigator>
      <last_name>Brent Tierney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thania Escamilla</last_name>
      <phone>702-851-4672</phone>
      <email>tescamilla@wccenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Karen McWhirter</last_name>
      <phone>702.851.4672</phone>
      <email>tescamilla@wccenter.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nicola Spirtos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center of Hope at Renown Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Pierpoint</last_name>
      <phone>775-225-5414</phone>
      <email>spierpoint@cohreno.com</email>
    </contact>
    <investigator>
      <last_name>Peter Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at Cooper</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Cooper</last_name>
      <phone>856-735-6237</phone>
      <email>cooper-walter@CooperHealth.edu</email>
    </contact>
    <contact_backup>
      <phone>855-632-2667</phone>
    </contact_backup>
    <investigator>
      <last_name>David Warshal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital South</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45459-447</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becca Wirth</last_name>
      <phone>937-208-2238</phone>
      <email>rswirth@premierhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>(937) 438-2400</last_name>
    </contact_backup>
    <investigator>
      <last_name>Michael Guy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Kern</last_name>
      <phone>360-597-1316</phone>
      <email>Julian.Kern@compassoncology.com</email>
    </contact>
    <investigator>
      <last_name>Erin Salinas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Austin-Balcones</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisca Fernandez</last_name>
      <phone>512-421-4183</phone>
      <email>francisca.fernandez@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>512-421-4250</phone>
    </contact_backup>
    <investigator>
      <last_name>Michael Teneriello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Austin-Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisca Fernandez</last_name>
      <phone>512-421-4183</phone>
      <email>francisca.fernandez@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Teneriello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Austin-North Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisca Fernandez</last_name>
      <phone>512-421-4183</phone>
      <email>francisca.fernandez@usoncology.com</email>
    </contact>
    <contact_backup>
      <phone>512-873-8900</phone>
    </contact_backup>
    <investigator>
      <last_name>Michael Teneriello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Wright</last_name>
      <phone>214-370-1763</phone>
      <email>jennifer.wright2@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carolyn Matthews</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104-2150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nori Sullivan</last_name>
      <phone>817-850-2011</phone>
      <email>nori.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Noelle Cloven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aide Borrego</last_name>
      <phone>956-992-0226</phone>
      <email>aide.bborrego@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Nurul Wahid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology San Antonio Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Bock</last_name>
      <phone>210-595-5355</phone>
      <email>Alice.Bock@usoncology.co</email>
    </contact>
    <investigator>
      <last_name>Antonio Santillan-Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479-4308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rowena Martinez</last_name>
      <phone>281-277-5200</phone>
      <email>rowena.martinez@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Kristy Ward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Lopez</last_name>
      <phone>281-296-0365</phone>
      <email>Ruth.Lopez1@usoncology.co</email>
    </contact>
    <investigator>
      <last_name>Christine Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Maxfield</last_name>
      <phone>903-579-9840</phone>
      <email>shelly.maxfield@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Deke Slayton Cancer Center</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Gray, CRC</last_name>
      <phone>281-332-7505</phone>
      <email>Tara.Gray@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Terri Pustilnik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendi Gobhardt</last_name>
      <phone>757-213-5813</phone>
      <email>wendi.gobhardt@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael McCollum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic-Gynecologic Oncology</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016-4962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Selvia</last_name>
      <phone>540-581-0240</phone>
      <email>djselvia@carilionclinic.org</email>
    </contact>
    <contact_backup>
      <phone>540-224-5170</phone>
    </contact_backup>
    <investigator>
      <last_name>David Iglesias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multicare Institute for Research and Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leann Harris</last_name>
      <phone>253-403-7249</phone>
      <email>lmharris@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Wafic Massry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KH der Barmherzigen Brüder Graz</name>
      <address>
        <city>Graz</city>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Schauer, Dr.</last_name>
      <phone>+43 (0)316 / 7067 - 13102</phone>
      <email>christian.schauer@bbgraz.at</email>
    </contact>
    <investigator>
      <last_name>Christian Schauer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ.-Klinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Petru, Prof. Dr.</last_name>
      <phone>+43 (0) 316 385 81648</phone>
      <email>Edgar.petru@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Edgar Petru, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ.-Klinik für Gynäkologie und Geburtshilfe, Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Marth, MD</last_name>
      <phone>+43 50 504 2305</phone>
      <email>Christian.marth@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christian Marth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Landesfrauenklinik Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pia Wolfrum-Ristau, Dr.</last_name>
      <phone>+43 (0)5 7255 57963</phone>
      <email>p.wolfrum-ristau@salk.at</email>
    </contact>
    <investigator>
      <last_name>Pia Wolfrum-Ristau, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis Bonheiden</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Van den Bulck, Dr.</last_name>
      <phone>+32 155 04 625</phone>
      <email>Heidi.Van.Den.Bulck@imelda.be</email>
    </contact>
    <investigator>
      <last_name>Heidi Van den Bulck, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi, Oncologie-Hématologie</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Honhon, Dr.</last_name>
      <phone>+ 32 71 10 47 41</phone>
      <email>Brigitte.Honhon@ghdc.be</email>
    </contact>
    <investigator>
      <last_name>Brigitte Honhon, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares, Clinical Trial Unit Medical Oncology - Integrated Cancer Center Ghent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christof Vulsteke, Prof.</last_name>
      <phone>+32 9 246 95 22</phone>
      <email>christof.vulsteke@azmmsj.be</email>
    </contact>
    <investigator>
      <last_name>Christof Vulsteke, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannelore Denys, Dr.</last_name>
      <phone>+32 9 32 26 92</phone>
      <email>hannelore.denys@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Hannelore Denys, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven, Leuven Cancer Institute</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joke de Roover</last_name>
      <email>joke.deroover@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Ignace Vergote, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Cornez, Dr.</last_name>
      <phone>+32 65 41 37 40</phone>
      <email>nathalie.cornez@hap.be</email>
    </contact>
    <investigator>
      <last_name>Nathalie Cornez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur - Site Ste Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Vuylsteke, Dr.</last_name>
      <phone>+32 81 72 07 73</phone>
      <email>peter.vuylsteke@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Peter Vuylsteke, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL-CUL Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel D'Hondt, Prof. Dr.</last_name>
      <phone>+32 8 142 38 45</phone>
      <email>lionel.dhondt@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Lionel D'Hondt, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologická Klinika Fakultní nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bohuslav Melichar, Prof. MUDr.</last_name>
      <phone>+420 588 444 522</phone>
      <email>bohuslav.melichar@fnol.cz</email>
    </contact>
    <investigator>
      <last_name>Bohuslav Melichar, Prof. MUDr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslav Klat, Dr.</last_name>
      <phone>+42 059 737 18 02</phone>
      <email>Jaroslav.klat@fno.cz</email>
    </contact>
    <investigator>
      <last_name>Jaroslav Klat, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynekologicko-porodnická klinika, Fakultní nemocnice Královské Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas Rob, Dr.</last_name>
      <phone>+420602574306</phone>
      <email>lukas.rob@fnkv.cz</email>
    </contact>
    <investigator>
      <last_name>Lukas Rob, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynekologicko-porodnická klinika 1. LF UK a VFN</name>
      <address>
        <city>Praha 2</city>
        <zip>128 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cibula, Prof. MUDr.</last_name>
      <phone>+420 224 967 451</phone>
      <email>dc@davidcibula.cz</email>
    </contact>
    <investigator>
      <last_name>David Cibula, Prof. MUDr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynekologicko-porodnické oddělení - Nemocnice České Budějovice a.s.</name>
      <address>
        <city>České Budějovice</city>
        <zip>370 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Valha, MUDr. Ph.D.</last_name>
      <phone>+ 420 604 335 24</phone>
      <email>petrvalha@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Valha, MUDr. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Wimberger, Prof. Dr.</last_name>
      <phone>+ 49 (0)351 458-4202</phone>
      <email>Pauline.wimberger@ukdd.de</email>
    </contact>
    <investigator>
      <last_name>Pauline Wimberger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nőgyógyászati Osztály, Országos Onkológiai Intézet</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Bagameri, Prof.</last_name>
      <phone>+36 30 9313155</phone>
      <email>bagameria@t-email.hu</email>
    </contact>
    <investigator>
      <last_name>Andrea Bagameri, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szuleszeti és Nogyogyaszati Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Poka, Prof.</last_name>
      <phone>+36 20 9216022</phone>
      <email>pokar@med.unideb.hu</email>
    </contact>
    <investigator>
      <last_name>Robert Poka, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilan Bruchim, Dr.</last_name>
      <phone>+972-4-6304995</phone>
      <email>ilan.bruchim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ilan Bruchim, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saare Zedek Medical Center - Gyneco-Oncology</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ora Solange Rosengarten, Dr.</last_name>
      <phone>+972-50-8685884</phone>
      <email>rosengarten@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Ora Solange Rosengarten, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Institute, Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayelet Shai, MD</last_name>
      <phone>+ 972-4-9107422</phone>
      <email>ayelets@gmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ayelet Shai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gyneco-Oncology Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Korach, MD</last_name>
      <phone>+972-50-7649502</phone>
      <email>jacob.korach@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Jacob Korach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Zamagni, Dr.</last_name>
      <phone>+39 3478014769</phone>
      <email>claudio.zamagni@aosp.bo.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Zamagni, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Antonio Perrino - ASL Brindisi</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saverio Cinieri, Prof.</last_name>
      <phone>+39 (0) 831537219</phone>
      <email>saverio.cinieri@asl.brindisi.it</email>
    </contact>
    <investigator>
      <last_name>Saverio Cinieri, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Lecco - Ospedale Manzoni, Dipartimento Oncologico</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Ardizzoia, Dr.</last_name>
      <phone>+ 39 0341489900</phone>
      <email>a.ardizzoia@asst-lecco.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Ardizzoia, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Medicina e Chirurgia, Università Milano-Bicocca, Direttore Programma Ginecologia Oncologica, Istituto Europeo Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicoletta Colombo, Prof.</last_name>
      <phone>+39 02943 72 183</phone>
      <email>nicoletta.colombo@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Nicoletta Colombo, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele, U.O. Ginecologia-Ematologia e TMO</name>
      <address>
        <city>Milano</city>
        <zip>60 20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgia Mangili, Dr.</last_name>
      <phone>+39 335 533 0365</phone>
      <email>mangili.giorgia@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Giorgia Mangili, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80130</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro Pignata, Dr.</last_name>
      <phone>+39 081 5903637</phone>
      <email>s.pignata@istitutotumori.na.it</email>
    </contact>
    <investigator>
      <last_name>Sandro Pignata, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Scambia, Prof.</last_name>
      <phone>+ 39 06 30154979</phone>
      <email>giovanni.scambia@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Scambia, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oddział Ginekologii Onkologicznej Katedry i Kliniki Onkologii Uniwersytetu Medycznego w Poznaniu</name>
      <address>
        <city>Poznań</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radosław Mądry, Prof.</last_name>
      <phone>+ 48 501149213</phone>
      <email>radoslaw.madry@skpp.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Radosław Mądry, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>lnstitut Catala d'Oncologia, Hospital Universitario Dr. Josep Trueta, Servicio de Oncologia,</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pilar Barretina Ginesta, Prof. Dr.</last_name>
      <phone>+ 34 972 22 58 34</phone>
      <email>mpbarretina@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Maria Pilar Barretina Ginesta, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra en Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Gonzalez Martin, Dr.</last_name>
      <phone>+ 34 91 353 19 20</phone>
      <email>agonzalezma@unav.es</email>
    </contact>
    <investigator>
      <last_name>Antonio Gonzalez Martin, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre. Servicio Oncología Médica</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Manso, Dr.</last_name>
      <phone>+ 34 91 390 80 03 8003</phone>
      <email>luigimanso@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luigi Manso, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynecological Tumor Center, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viola Heinzelmann-Schwarz, Prof.</last_name>
      <phone>+41 61 556 58 83</phone>
      <email>viola.heinzelmann@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Viola Heinzelmann-Schwarz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IOSI Bellinzona, Oncology Institute of Southern Switzerland, Ospedale San Giovanni</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Del Grande, Dr.</last_name>
      <phone>+41(0)91 811 8924</phone>
      <email>Maria.DelGrande@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Maria Del Grande, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Frauenfeld - Frauenklinik</name>
      <address>
        <city>Frauenfeld</city>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Fehr, Prof. Dr.</last_name>
      <phone>+41 52 723 7711</phone>
      <email>mathias.fehr@stgag.ch</email>
    </contact>
    <investigator>
      <last_name>Mathias Fehr, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich - Klinik für Gynäkologie</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleftherios Pierre Samartzis, Dr. med.</last_name>
      <phone>+41 44 255 13 88</phone>
      <email>eleftherios.samartzis@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Eleftherios Pierre Samartzis, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95.</citation>
    <PMID>15126372</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. Epub 2007 Jun 5.</citation>
    <PMID>17551011</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.</citation>
    <PMID>22608262</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26(7):633-40. doi: 10.1007/s10585-009-9262-y. Epub 2009 Apr 23.</citation>
    <PMID>19387848</PMID>
  </reference>
  <reference>
    <citation>Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015 Dec 11;5:18046. doi: 10.1038/srep18046.</citation>
    <PMID>26658786</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.</citation>
    <PMID>26670971</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum in: JAMA. 2018 May 1;319(17):1824.</citation>
    <PMID>29260225</PMID>
  </reference>
  <reference>
    <citation>Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Gynecol Oncol. 2018 Sep;150(3):471-477. doi: 10.1016/j.ygyno.2018.07.018. Epub 2018 Jul 27.</citation>
    <PMID>30060963</PMID>
  </reference>
  <reference>
    <citation>Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.</citation>
    <PMID>29392280</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platinum Resistant Ovarian Cancer</keyword>
  <keyword>TTFields</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Minimal toxicity</keyword>
  <keyword>TTF</keyword>
  <keyword>Tumor Treating Fields</keyword>
  <keyword>Novocure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

